Literature DB >> 23255077

Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.

Meenakshi Bothra1, Rachna Seth, Arti Kapil, S N Dwivedi, Shinjini Bhatnagar, Immaculata Xess.   

Abstract

OBJECTIVES: To identify predictors associated with adverse outcome in febrile neutropenic episodes among pediatric oncology patients between 1 and 18 y age, to ascertain the prevalence of invasive bacterial or fungal infection/mortality, to determine the common organisms causing invasive bacterial infection in children with febrile neutropenia and to evaluate their current antimicrobial sensitivity pattern.
METHODS: It was an observational descriptive study conducted between February 2009 through July 2010. Febrile neutropenic episodes satisfying the inclusion criteria were enrolled. Relevant history was taken followed by a detailed clinical examination and laboratory examination. Logistic Regression analysis was used to identify significant predictors of adverse outcome in febrile neutropenic episodes.
RESULTS: Out of the 155 febrile neutropenic episodes studied, adverse outcome occurred in 53(34 %) of the episodes. History of three or more previous episodes of febrile neutropenia, child being already on oral antibiotics and Chest Radiograph abnormality at presentation were found to be significantly associated with adverse outcome on multivariate logistic regression analysis. Documented invasive bacterial and fungal infection was seen in 27.8 % and 14.2 % episodes. Mortality occurred in 8 (5 %) of episodes. Gram negative bacterial infections were more common. Most common bacteria isolated was Escherichia coli and the commonest gram positive organism isolated was Staphylococcus aureus (MSSA).
CONCLUSIONS: On multivariate analysis, the variables found to be significantly associated with adverse outcome in febrile neutropenic episodes were three or more previous episodes of febrile neutropenia, child being already on oral antibiotics and Chest Radioraph abnormality at presentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255077     DOI: 10.1007/s12098-012-0925-3

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  17 in total

1.  Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever.

Authors:  M E Santolaya; A M Alvarez; A Becker; J Cofré; N Enríquez; M O'Ryan; E Payá; J Pilorget; C Salgado; J Tordecilla; M Varas; M Villarroel; T Viviani; M Zubieta
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

2.  The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.

Authors:  Shereen Mohamed El-Maghraby; Manar Mohamed Moneer; Manar Mohamed Ismail; Lobna M Shalaby; Hadir Ahmed El-Mahallawy
Journal:  J Pediatr Hematol Oncol       Date:  2007-03       Impact factor: 1.289

3.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

4.  Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes.

Authors:  Sameer Bakhshi; K S Padmanjali; L S Arya
Journal:  Pediatr Hematol Oncol       Date:  2008-06       Impact factor: 1.969

Review 5.  Optimum management of pediatric patients with fever and neutropenia.

Authors:  Aditya H Gaur; Patricia M Flynn; Jerry L Shenep
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

6.  A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer.

Authors:  Hugo R Paganini; Clarisa Aguirre; Gabriela Puppa; Cecilia Garbini; Javier Ruiz Guiñazú; Gabriela Ensinck; Claudia Vrátnica; Luis Flynn; Marisa Iacono; Pedro Zubizarreta
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

7.  A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes.

Authors:  P Mathur; R Chaudhry; L Kumar; A Kapil; B Dhawan
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 8.  Bloodstream infections in cancer patients with febrile neutropenia.

Authors:  Ronald Feld
Journal:  Int J Antimicrob Agents       Date:  2008-09-07       Impact factor: 5.283

9.  Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan.

Authors:  Hsin-Pao Lai; Po-Ren Hsueh; Yee-Chun Chen; Ping-Ing Lee; Chun-Yi Lu; Meng-Yao Lu; Wen-Chuan Lin; Yu-Chia Hsieh; Chin-Yun Lee; Kai-Hsin Lin; Li-Min Huang
Journal:  J Microbiol Immunol Infect       Date:  2003-09       Impact factor: 4.399

10.  Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia.

Authors:  Heather Hodgson-Viden; Paul E Grundy; Joan L Robinson
Journal:  BMC Pediatr       Date:  2005-05-18       Impact factor: 2.125

View more
  6 in total

1.  Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study.

Authors:  Jogender Kumar; Amitabh Singh; Rachna Seth; Immaculata Xess; Manisha Jana; Sushil Kumar Kabra
Journal:  Indian J Pediatr       Date:  2018-06-29       Impact factor: 1.967

2.  Can complications in febrile neutropenia be predicted? Report from a developing country.

Authors:  Sapna Oberoi; Anirban Das; Amita Trehan; Pallab Ray; Deepak Bansal
Journal:  Support Care Cancer       Date:  2017-06-11       Impact factor: 3.603

3.  Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings.

Authors:  Sheena Mukkada; Jeannette Kirby; Nopporn Apiwattanakul; Randall T Hayden; Miguela A Caniza
Journal:  Curr Clin Microbiol Rep       Date:  2016-04-18

4.  The Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer.

Authors:  Mustafa Buyukavci; Zuhal Keskin Yildirim
Journal:  Eurasian J Med       Date:  2019-06

5.  Risk stratification in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules.

Authors:  Gabrielle M Haeusler; Karin A Thursky; Monica A Slavin; Franz E Babl; Richard De Abreu Lourenco; Zoe Allaway; Francoise Mechinaud; Robert Phillips
Journal:  EClinicalMedicine       Date:  2020-01-07

Review 6.  Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy.

Authors:  Federica Cennamo; Riccardo Masetti; Prisca Largo; Alberto Argentiero; Andrea Pession; Susanna Esposito
Journal:  Children (Basel)       Date:  2021-11-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.